Global Vitiligo Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Vitiligo treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Aclaris Therapeutics Inc, Arrien Pharmaceuticals LLC, Axim Biotechnologies Inc, Boston Pharmaceuticals Inc, Bristol-Myers Squibb Co and others.
A Significant contribution to the Vitiligo pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Vitiligo pipeline included 12 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Vitiligo condition and increased access to investments is encouraging growth of Vitiligo drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Vitiligo drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Vitiligo therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Vitiligo pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Vitiligo. Further, orphan drug status, fast track designation, grants awarded and other special status for Vitiligo pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Vitiligo pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Vitiligo Pipeline candidates-
A Significant contribution to the Vitiligo pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Vitiligo pipeline included 12 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Vitiligo condition and increased access to investments is encouraging growth of Vitiligo drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Vitiligo drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Vitiligo therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Vitiligo pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Vitiligo. Further, orphan drug status, fast track designation, grants awarded and other special status for Vitiligo pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Vitiligo pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Vitiligo Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Vitiligo drugs
- Late phase: Phase 3 and in-approval Vitiligo drugs
- Company overview
- Snapshot
- Vitiligo therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Vitiligo- Disease Overview
2.2 Vitiligo- Pipeline Snapshot
2.3 Vitiligo- Pipeline Drugs by Phase
2.4 Vitiligo- Pipeline Drugs by Company
2.5 Vitiligo- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Aclaris Therapeutics Inc Vitiligo Drug Pipeline, H2- 2019
3.2 Arrien Pharmaceuticals LLC Vitiligo Drug Pipeline, H2- 2019
3.3 Axim Biotechnologies Inc Vitiligo Drug Pipeline, H2- 2019
3.4 Boston Pharmaceuticals Inc Vitiligo Drug Pipeline, H2- 2019
3.5 Bristol-Myers Squibb Co Vitiligo Drug Pipeline, H2- 2019
3.6 Celgene Corp Vitiligo Drug Pipeline, H2- 2019
3.7 Clinuvel Pharmaceuticals Ltd Vitiligo Drug Pipeline, H2- 2019
3.8 Incyte Corp Vitiligo Drug Pipeline, H2- 2019
3.9 JN Biosciences LLC Vitiligo Drug Pipeline, H2- 2019
3.10 Pfizer Vitiligo Drug Pipeline, H2- 2019
3.11 Portola Pharmaceuticals Inc Vitiligo Drug Pipeline, H2- 2019
3.12 Rheos Medicines Inc Vitiligo Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Vitiligo- Phase 1 Drug Details
4.2 Vitiligo- Phase 1 Drug Overview
4.3 Vitiligo- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Vitiligo- Phase 2 Drug Details
5.2 Vitiligo- Phase 2 Drug Overview
5.3 Vitiligo- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Vitiligo- Phase 3 Drug Details
6.2 Vitiligo- Phase 3 Drug Overview
6.3 Vitiligo- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Vitiligo- Pre-clinical Phase Drug Details
7.2 Vitiligo- Pre-clinical Phase Drug Overview
7.3 Vitiligo- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Vitiligo- Disease Overview
2.2 Vitiligo- Pipeline Snapshot
2.3 Vitiligo- Pipeline Drugs by Phase
2.4 Vitiligo- Pipeline Drugs by Company
2.5 Vitiligo- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Aclaris Therapeutics Inc Vitiligo Drug Pipeline, H2- 2019
3.2 Arrien Pharmaceuticals LLC Vitiligo Drug Pipeline, H2- 2019
3.3 Axim Biotechnologies Inc Vitiligo Drug Pipeline, H2- 2019
3.4 Boston Pharmaceuticals Inc Vitiligo Drug Pipeline, H2- 2019
3.5 Bristol-Myers Squibb Co Vitiligo Drug Pipeline, H2- 2019
3.6 Celgene Corp Vitiligo Drug Pipeline, H2- 2019
3.7 Clinuvel Pharmaceuticals Ltd Vitiligo Drug Pipeline, H2- 2019
3.8 Incyte Corp Vitiligo Drug Pipeline, H2- 2019
3.9 JN Biosciences LLC Vitiligo Drug Pipeline, H2- 2019
3.10 Pfizer Vitiligo Drug Pipeline, H2- 2019
3.11 Portola Pharmaceuticals Inc Vitiligo Drug Pipeline, H2- 2019
3.12 Rheos Medicines Inc Vitiligo Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Vitiligo- Phase 1 Drug Details
4.2 Vitiligo- Phase 1 Drug Overview
4.3 Vitiligo- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Vitiligo- Phase 2 Drug Details
5.2 Vitiligo- Phase 2 Drug Overview
5.3 Vitiligo- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Vitiligo- Phase 3 Drug Details
6.2 Vitiligo- Phase 3 Drug Overview
6.3 Vitiligo- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Vitiligo- Pre-clinical Phase Drug Details
7.2 Vitiligo- Pre-clinical Phase Drug Overview
7.3 Vitiligo- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
